News Sentiment

DRMA sentiment intelligence

Dermata Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.33 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-0.7% over one week, +13.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to earnings forward of Dermata Therapeutics, Inc. – NASDAQ:DRMAW

Market Reaction

Balanced read

47/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -0.7% Price digesting
Trend fit Trend inactive 13.7% over four weeks
Fair value -96.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 33
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
TradingKey 10
Stock Titan 10
Market source 6
timothysykes.com 3
simplywall.st 2
Finviz 1
Minichart 1

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 17
Balance sheet 3
Deals and strategy 2
Capital return 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-48 of 48
Simply Wall Street Direct company coverage

Dermata Therapeutics (Nasdaq:DRMA) - Stock Analysis

This analysis of Dermata Therapeutics (Nasdaq:DRMA) highlights its current market cap of US$5.2m and a highly undervalued analyst price target of US$4.00, despite significant past share price declines. The company faces major risks including having less than a year of cash runway

Tone
Negative 31/100
Event
Analyst action
Published
26 May 2026 20:40
Source
Simply Wall Street
Stock Titan Direct company coverage

Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants

Dermata Therapeutics (NASDAQ: DRMA) has filed a shelf registration statement (S-3/A) to sell up to $100 million in various securities, including common stock, preferred stock, warrants, and debt securities. This filing indicates the company's strategic shift from Rx dermatology t

Tone
Negative 40/100
Event
Balance sheet
Published
22 May 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

Once-weekly Tome mask aims to bring professional skincare home by mid-2026

Dermata Therapeutics is pivoting to a direct-to-consumer skincare model with its new Tome brand, aiming to launch its first product, a once-weekly Foundational Treatment mask, in mid-2026. The company reported $6.9 million in cash and cash equivalents as of Q1 2026, with funding

Tone
Positive 65/100
Event
Balance sheet
Published
13 May 2026 20:38
Source
Stock Titan